Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.

Meshaal Alanzi Mohammad Abu-TinehLajos SzabadosM Z Sharaf EldeanSali AlatasiRuba Y TahaSarah A Elkourashy

Published in: OncoTargets and therapy (2023)

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

Keyphrases

diffuse large b cell lymphoma
high intensity
hodgkin lymphoma
acute myeloid leukemia
stem cells
resistance training
rheumatoid arthritis
electronic health record
locally advanced
disease activity
machine learning
mesenchymal stem cells
artificial intelligence
rectal cancer
smoking cessation